US Vaccines Market

The report "US Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Forecast to 2029", US vaccines market (excluding COVID-19 vaccines) is projected to reach USD 38.44 Billion by 2029 from USD 25.98 Billion in 2024, at a CAGR of 8.2% during the forecast period. The growth in the US vaccines market is fueled by various factors such as launch of RSV vaccines, increasing investments by government and non-government organizations for vaccine development and increasing R&D investments by market players.

Browse 151 market data tables and 57 figures and in-depth TOC on “US Vaccines Market - Forecast to 2029."
Early buyers will receive 10% customization on reports.

To know about the assumptions considered for the study download the pdf brochure

The conjugate vaccine segment is expected to have the dominant share of the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on technology, the US vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. In 2023, conjugate vaccine segment dominated the US vaccine market. Rising awareness and preventive healthcare initiatives, increasing pediatric immunization programs, and favorable government & regulatory environments have further bolstered the prominence of conjugated vaccines.

The HPV segment is expected to account for the largest share of the disease indication segment in the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on disease indication, the US vaccines market (excluding COVID-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV and other disease indications. RSV vaccine segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Growing investments in vaccine R&D and novel technologies coupled with high disease burden among infants and older adults has fueled demand for RSV vaccines.

The multivalent vaccines segment is expected to account for the largest share of the type segment in the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on type, the US vaccines market (excluding COVID-19 vaccines) is segmented into monovalent and multivalent vaccines. Multivalent vaccines segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Advancements in recombinant and conjugate vaccine technologies and increased investment by pharmaceutical companies in R&D for next-generation multivalent vaccines has fueled demand for multivalent vaccines.

The US vaccines market is consolidated, with a small number of players competing for market share. Merck & Co., Inc (US) Pfizer Inc. (US), Emergent (US), Johnson & Johnson Services, Inc (US), Novavax, Inc. (US), Inovio Pharmaceuticals (US), VBI Vaccines (US) and among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the US market.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/